Market Research Logo

Autism - Pipeline Review, H2 2015

Autism - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Autism - Pipeline Review, H2 2015’, provides an overview of the Autism’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Autism
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Autism and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Autism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Autism pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Autism
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Autism pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Autism Overview
Therapeutics Development
Pipeline Products for Autism - Overview
Pipeline Products for Autism - Comparative Analysis
Autism - Therapeutics under Development by Companies
Autism - Therapeutics under Investigation by Universities/Institutes
Autism - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Autism - Products under Development by Companies
Autism - Products under Investigation by Universities/Institutes
Autism - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
BioCrea GmbH
BrainStorm Cell Therapeutics Inc.
Cellceutix Corporation
Confluence Pharmaceuticals LLC
Curemark, LLC
Egenix, Inc.
F. Hoffmann-La Roche Ltd.
Heptares Therapeutics Limited
Intra-Cellular Therapies, Inc.
MedDay
Merz Pharma GmbH & Co. KgaA
Mnemosyne Pharmaceuticals, Inc.
Omeros Corporation
Otsuka Holdings Co., Ltd.
Retrophin Inc.
Reviva Pharmaceuticals Inc.
Saniona AB
Sumitomo Dainippon Pharma Co., Ltd.
Autism - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(dextromethorphan hydrobromide + quinidine sulfate) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
acamprosate calcium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADX-71441 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADX-88178 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aripiprazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
aripiprazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carbetocin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CM-AT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CN-2097 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Autism - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HTL-14242 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ITI-007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KM-391 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lurasidone hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MD-1103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
memantine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oxytocin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RG-7314 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RO-5285119 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RP-5063 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Agonize GABAA Receptor Subunit Alpha-5 for Autism - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Modulate GABRA5 Receptor for CNS Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Target GPR63 for Autism - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Agonize GABAA-Beta 2 Receptor for Epilepsy and Autism - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize NMDA2A for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Translation Initiation Factor-4E for Cancer and Autism - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Target Oxytocin for Autism and Anxiety Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Multiple Sclerosis, Rheumatoid Arthritis, Autism and Bronchopulmonary Dysplasia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Neurodegenerative Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
suramin hexasodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VU-0410120 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autism - Recent Pipeline Updates
Autism - Dormant Projects
Autism - Discontinued Products
Autism - Product Development Milestones
Featured News & Press Releases
Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus' Once-Weekly Transdermal Aripiprazole
Jun 10, 2015: Clinical trial launched to assess safety and efficacy of autism drug treatment
May 11, 2015: Curemark Launches New Phase III Trial in Expanded Population of Children with Autism
Nov 04, 2013: Curemark Begins NDA Submission for CM-AT Autism Treatment
Apr 23, 2013: Curemark Announces Positive Pre-NDA Meeting With FDA For New Drug Application For CM-AT For Autism
Mar 13, 2013: Researchers Use Old Drug Treatment To Correct Autism Symptoms In Mouse Model
Aug 15, 2012: Omeros Unlocks Over Half Of Class A Orphan G Protein-Coupled Receptors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Autism, H2 2015
Number of Products under Development for Autism - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Autism - Pipeline by Addex Therapeutics Ltd, H2 2015
Autism - Pipeline by BioCrea GmbH, H2 2015
Autism - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2015
Autism - Pipeline by Cellceutix Corporation, H2 2015
Autism - Pipeline by Confluence Pharmaceuticals LLC, H2 2015
Autism - Pipeline by Curemark, LLC, H2 2015
Autism - Pipeline by Egenix, Inc., H2 2015
Autism - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Autism - Pipeline by Heptares Therapeutics Limited, H2 2015
Autism - Pipeline by Intra-Cellular Therapies, Inc., H2 2015
Autism - Pipeline by MedDay, H2 2015
Autism - Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2015
Autism - Pipeline by Mnemosyne Pharmaceuticals, Inc., H2 2015
Autism - Pipeline by Omeros Corporation, H2 2015
Autism - Pipeline by Otsuka Holdings Co., Ltd., H2 2015
Autism - Pipeline by Retrophin Inc., H2 2015
Autism - Pipeline by Reviva Pharmaceuticals Inc., H2 2015
Autism - Pipeline by Saniona AB, H2 2015
Autism - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Autism Therapeutics - Recent Pipeline Updates, H2 2015
Autism - Dormant Projects, H2 2015
Autism - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Autism, H2 2015
Number of Products under Development for Autism - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report